Condition: COVID-19 · Sponsor: University Hospital Schleswig-Holstein
COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level: In order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals. Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.
This description comes directly from the study's public registry record.
Stefan Schreiber, Prof. Dr. · 0049 (0)431 500 22201 · s.schreiber@mucosa.de
Thomas Bahmer, Prof. Dr. · 0049 (0) 431 500 62629 · thomas.bahmer@uksh.de
Always discuss trial participation with your own doctor first.
| University Hospital Wuerzburg | Würzburg, Bavaria, Germany | Not Yet Recruiting |
| University Hospital Schleswig-Holstein, Campus Kiel | Kiel, Schleswig-Holstein, Germany | Recruiting |
| University Hospital Charité Berlin | Berlin, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04679584